- Home
- ENSC vs CYCN Comparison
ENSC vs CYCN Comparison
Compare ENSC & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- CYCN
- Stock Information
- Founded
- ENSC 2003
- CYCN 2018
- Country
- ENSC United States
- CYCN United States
- Employees
- ENSC N/A
- CYCN N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- CYCN Health Care
- Exchange
- ENSC Nasdaq
- CYCN Nasdaq
- Market Cap
- ENSC 6.4M
- CYCN 7.6M
- IPO Year
- ENSC N/A
- CYCN N/A
- Fundamental
- Price
- ENSC $2.27
- CYCN $2.43
- Analyst Decision
- ENSC
- CYCN
- Analyst Count
- ENSC 0
- CYCN 0
- Target Price
- ENSC N/A
- CYCN N/A
- AVG Volume (30 Days)
- ENSC 149.6K
- CYCN 1.1M
- Earning Date
- ENSC 11-11-2025
- CYCN 11-13-2025
- Dividend Yield
- ENSC N/A
- CYCN N/A
- EPS Growth
- ENSC N/A
- CYCN N/A
- EPS
- ENSC N/A
- CYCN N/A
- Revenue
- ENSC $7,413,722.00
- CYCN $2,174,000.00
- Revenue This Year
- ENSC N/A
- CYCN N/A
- Revenue Next Year
- ENSC $1,354.55
- CYCN N/A
- P/E Ratio
- ENSC N/A
- CYCN N/A
- Revenue Growth
- ENSC 415.58
- CYCN N/A
- 52 Week Low
- ENSC $1.62
- CYCN $1.27
- 52 Week High
- ENSC $14.67
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- ENSC 51.69
- CYCN 46.28
- Support Level
- ENSC $2.35
- CYCN $2.17
- Resistance Level
- ENSC $2.63
- CYCN $2.56
- Average True Range (ATR)
- ENSC 0.19
- CYCN 0.33
- MACD
- ENSC 0.01
- CYCN -0.01
- Stochastic Oscillator
- ENSC 34.60
- CYCN 15.00
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.